Diet control and BMI impact on Metformin response in type 2 Diabetes mellitus patients
Abstract
OBJECTIVE: Aim: To assess the impact of BMI and diet control on variation in response to metformin monotherapy in Iraqi people with type 2 DM.
PATIENTS AND METHODS: Materials and Methods: a cross-sectional study included 150 patients who met specific criteria, such as being between 30 and 70 years old, diagnosed with type 2 diabetes, and on a daily dose of 1000 mg metformin as a monotherapy for at least three months. Data collected included body mass index (BMI) and glycemic control parameters such as: glycated hemoglobin (HbA1c) levels, fasting blood glucose levels, fasting serum insulin levels, HOMA-IR, and insulin sensitivity. The patients according to their metformin response classified into two groups based on HbA1c as following: poor (HbA1c≥6.5% and good (HbA1c≤6.5%) responder's patients.
RESULTS: Results: The statistical analysis suggests that there is no meaningful distinction in glycemic control parameters when comparing good and poor responders within specific BMI subgroups and among individuals practicing diet control. However, in a broader context, it is evident that glycemic control parameters tend to be lower in patients with lower BMI and those who are following a controlled diet.
CONCLUSION: Conclusions: The correlation between diet control and BMI with glycemic control in diabetic patients, underscoring the significance of lifestyle adjustments in the management of diabetes.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 150 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.